Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | FRK | P42685 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 13/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 13/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5355304 | 0.84 | MAPK14 (0.42) | TGFBR1MAP4K4EGFRMAPK9CSNK1A1 | |
| SCHEMBL5347433 | 0.84 | CSNK1E (0.43) | TGFBR1MAP4K4EGFRFRKMAPK9 | |
| SCHEMBL5359379 | 0.83 | CTSS (0.37) | CTSSTGFBR1MAP4K4MAPK9CSNK1A1 | |
| SCHEMBL5356614 | 0.82 | TGFBR1 (0.36) | TGFBR1MAP4K4EGFRFRKMAPK9 | |
| SCHEMBL5354662 | 0.80 | MAP4K4 (0.38) | MAP4K4EGFRFRKMAPK9CSNK1A1 | |
| SCHEMBL5356860 | 0.79 | CSNK1D (0.38) | CTSSTGFBR1CSNK1DCSNK1EMAPK14 | |
| SCHEMBL5359372 | 0.79 | CTSS (0.38) | CTSSTGFBR1MAPK9CSNK1DCSNK1E | |
| SCHEMBL5350468 | 0.77 | TGFBR1 (0.41) | TGFBR1CSNK1DCSNK1EPTGS2MAPK14 | |
| SCHEMBL5356381 | 0.77 | KDR (0.52) | TGFBR1MAP4K4EGFRMAPK9CSNK1A1 | |
| SCHEMBL5349499 | 0.76 | MAPK14 (0.48) | MAP4K4FRKMAPK9CSNK1A1CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553096-B1 | PYRAZOLE COMPOUNDS | UBE INDUSTRIES (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-7294625-B2 | Pyrazole compounds | UBE INDUSTRIES, LTD. (JP) | 2007-11-13 | — | — | US | disclosed |
| US-20060063934-A1 | 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis | UBE INDUSTRIES, LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1553096-A1 | PYRAZOLE COMPOUNDS | Ube Industries, Ltd. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063934-A1 | 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis | CNKSR1, MAPK1, MAPK3 | CTSS 3999/4885TGFBR1 1215/4885MAP4K4 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.